[February 20, 2017]

Vulval Atrophy - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 - Research and Markets

Research and Markets has announced the addition of the "Vulval Atrophy - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" drug pipelines to their offering.

Vulval Atrophy - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

A key objective of the Vulval Atrophy Report is to understand the market and pipeline status of the drugs around the Vulval Atrophy to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The eport provides the historical and forecasted sales of the drugs till 2018.

The Vulval Atrophy Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Vulval Atrophy.

While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Key Topics Covered:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Vulval Atrophy

7. Phase III Drugs for Vulval Atrophy

8. Discontinued Drugs for Vulval Atrophy

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/z8b43q/vulval_atrophy

View source version on businesswire.com: http://www.businesswire.com/news/home/20170220005391/en/

[ Back To TMCnet.com's Homepage ]